Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression

Zeng,Huizhi; He,Yi; Yu,Yang; Zhang,Jiashu; Zeng,Xiaona; Gong,Fengtao; Liu,Qi; Yang,Bo

doi:10.3892/mmr.2017.7960

Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression

Authors:
- Huizhi Zeng
- Yi He
- Yang Yu
- Jiashu Zhang
- Xiaona Zeng
- Fengtao Gong
- Qi Liu
- Bo Yang
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China, College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
Published online on: November 3, 2017 https://doi.org/10.3892/mmr.2017.7960
Pages: 918-924
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Voiding dysfunction is the primary clinical manifestation of chronic prostatitis (CP), which is a common urological disease. The present study investigated whether prostate fibrosis was associated with urinary dysfunction in CP and if resveratrol improved urinary dysfunction, and the underlying molecular mechanism. A rat model of CP was established via subcutaneous injections of the pertussis‑diphtheria‑tetanus vaccine, which was followed by treatment with resveratrol. Bladder pressure and volume tests were performed to investigate the effect of resveratrol on urinary dysfunction in CP rats. Western blotting and immunohistochemical staining examined the expression levels of tryptase, chymase, transforming growth factor (TGF)‑β, Wnt and α‑smooth muscle actin (α‑SMA). The results demonstrated that the maximum capacity of the bladder, residual urine volume and maximum voiding pressure were increased significantly in the CP group compared with the control group. Mast cell (MC) activation, the activity of TGF‑β/Wnt/β‑catenin pathways, and the expression levels of tryptase and α‑SMA in the CP group were increased significantly compared with the control group. Resveratrol treatment significantly reversed these factors. Therefore, the results indicate that MC infiltration may induce prostate fibrosis, which exhibits a close association with urinary dysfunction in CP. Resveratrol may improve fibrosis via the suppression of MC activation and TGF‑β/Wnt/β‑catenin pathway activities.

View Figures

View References

1	Tyagi P, Kashyap M, Pore S, Wang Z and Yoshimura N: MP25-07 prostatic inflammation evokes upergulation of neurotrophins in sensory ganglia: Possible contribution to dysfunctional voiding. J Urol. 193:e2872015. View Article : Google Scholar
2	Liao LM, Shi BY and Liang CQ: Ambulatory urodynamic monitoring of external urethral sphincter behavior in chronic prostatitis patients. Asian J Androl. 1:215–217. 1999.PubMed/NCBI
3	Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM and Macoska JA: Prostatic fibrosis is associated with lower urinary tract symptoms. J Urolo. 188:1375–1381. 2012. View Article : Google Scholar
4	Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T and Schuppan D: Collagen and tissue turnover as a function of age: Implications for fibrosis. J Hepatol. 64:103–109. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fabre V, Wu H, PondTor S, Coutinho H, Acosta L, Jiz M, Olveda R, Cheng L, White ES, Jarilla B, et al: Tissue inhibitor of matrix-metalloprotease1 predicts risk of hepatic fibrosis in human schistosoma japonicum infection. J Infect Dis. 203:707–714. 2011. View Article : Google Scholar : PubMed/NCBI
6	Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste NE, Bisoffi M and Griffith JK: Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 129:1310–1321. 2011. View Article : Google Scholar : PubMed/NCBI
7	Silver RB: Role of mast cells in renal fibrosis. Kidney Int. 84:2142013. View Article : Google Scholar : PubMed/NCBI
8	Cruse G and Bradding P: Mast cells in airway diseases and interstitial lung disease. Eur J Pharma. 778:125–138. 2016. View Article : Google Scholar
9	Gaca MDA, Arthur MJP and Benyon RC: Mast cell protease and stem cell factor expression in rat liver fibrosis. J Hepatol. 28:811998. View Article : Google Scholar
10	Yadav A, Desai RS, Bhuta BA, Singh JS, Mehta R and Nehete AP: Altered immunohistochemical expression of mast cell tryptase and chymase in the pathogenesis of oral submucous fibrosis and malignant transformation of the overlying epithelium. PLoS One. 9:e987192014. View Article : Google Scholar : PubMed/NCBI
11	Zerr P, Palumbo-Zerr K, Huang J, Tomcik M, Sumova B, Distler O, Schett G and Distler JH: Sirt1 regulates canonical TGF-(β) signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis. 75:226–233. 2016. View Article : Google Scholar : PubMed/NCBI
12	Summers SA, Gan PY, Dewage L, Ma FT, Ooi JD, O'Sullivan KM, Nikolic-Paterson DJ, Kitching AR and Holdsworth SR: Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction. Kidney Int. 82:676–685. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ and Jeong KS: Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCI(4)-induced hepatic fibrosis. World J Gastroenterol. 11:1141–1148. 2005. View Article : Google Scholar : PubMed/NCBI
14	Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, et al: Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 3:7352012. View Article : Google Scholar : PubMed/NCBI
15	Torres P, Poveda A, Jimenez-Barbero J, Ballesteros A and Plou FJ: Regioselective lipase-catalyzed synthesis of 3-o-acyl derivatives of resveratrol and study of their antioxidant properties. J Agric Food Chem. 58:807–813. 2010. View Article : Google Scholar : PubMed/NCBI
16	Sharma S, Anjaneyulu M, Kulkarni SK and Chopra K: Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology. 76:69–75. 2006. View Article : Google Scholar : PubMed/NCBI
17	Csiszar A: Anti-inflammatory effects of resveratrol: Possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci. 1215:117–122. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gharaee-Kermani M, Moore BB and Macoska JA: Resveratrol-mediated repression and reversion of prostatic myofibroblast phenoconversion. PLoS One. 11:e01583572016. View Article : Google Scholar : PubMed/NCBI
19	He Y, Zeng H, Yu Y, Zhang J, Zeng X, Gong F, Duan X, Liu Q and Yang B: Resveratrol improved the progression of chronic prostatitis via the downregulation of c-kit/SCF by activating Sirt1. J Agric Food Chem. 65:5668–5673. 2017. View Article : Google Scholar : PubMed/NCBI
20	He Y, Zeng HZ, Yu Y, Zhang JS, Duan X, Zeng XN, Gong FT, Liu Q and Yang B: Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis. Environ Toxicol Pharmacol. 54:120–124. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wong L, Done JD, Schaeffer AJ and Thumbikat P: Experimental autoimmune prostatitis induces microglial activation in the spinal cord. Prostate. 75:50–59. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zheng T, Wang R, Zhang TB, Jia DH, Wang CL, Sun Y and Zhang WX: AB036. Effects and its potential mechanisms of Cox-2 inhibitors on ejaculation latency of rat with experimental autoimmune prostatitis. Transl Androl Urol. 5 Suppl 1:AB0362016. View Article : Google Scholar :
23	Rivero VE, Motrich RD, Maccioni M and Riera CM: Autoimmune etiology in chronic prostatitis syndrome: An advance in the understanding of this pathology. Crit Rev Immunol. 27:33–46. 2007. View Article : Google Scholar : PubMed/NCBI
24	Fraga F, Sturny M, Ruoccolo R, Santos R, Silva R and Stergiopulos N: 139 Angiotensin-(1–7) inhibits cavernosal fibrosis via attenuation of fibroblast differentiation to myofibroblast. J Sex Med. 14 Suppl 1:S392017. View Article : Google Scholar
25	Abe M, Kurosawa M, Ishikawa O, Miyachi Y and Kido H: Mast cell tryptase stimulates both human dermal fibroblast proliferation and type I collagen production. Clin Exp Allergy. 28:1509–1517. 1998. View Article : Google Scholar : PubMed/NCBI
26	Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF and Graham MF: Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem. 272:7127–7131. 1997. View Article : Google Scholar : PubMed/NCBI
27	Li J, Jubair S, Levick SP and Janicki JS: The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metabolic and Endocr. 10:16–23. 2016. View Article : Google Scholar
28	Beghdadi W, Madjene LC, Claver J, Pejler G, Beaudoin L, Lehuen A, Daugas E and Blank U: Mast cell chymase protects against renal fibrosis in murine unilateral ureteral obstruction. Kidney Int. 84:317–326. 2013. View Article : Google Scholar : PubMed/NCBI
29	Globa T, Saptefrţi L, Ceauşu RA, Gaje P, Cimpean AM and Raica M: Mast cell phenotype in benign and malignant tumors of the prostate. Pol J Pathol. 65:147–153. 2014. View Article : Google Scholar : PubMed/NCBI
30	Qi L, Song W, Liu Z, Zhao X, Cao W and Sun B: Wnt3a promotes the vasculogenic mimicry formation of colon cancer via wnt/β-catenin signaling. Int J Mol Sci. 16:18564–18579. 2015. View Article : Google Scholar : PubMed/NCBI
31	Conidi A, van den Berghe V and Huylebroeck D: Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling. Int J Mol Sci. 14:6690–6719. 2013. View Article : Google Scholar : PubMed/NCBI
32	Pons M, Ali L, Beghdadi W, Danelli L, Alison M, Madjène LC, Calvo J, Claver J, Vibhushan S, Åbrink M, et al: Mast cells and MCPT4 chymase promote renal impairment after partial ureteral obstruction. Front Immunol. 8:4502017. View Article : Google Scholar : PubMed/NCBI
33	van den Bosch MH, Blom AB, van Lent PL, van Beuningen HM, Blaney Davidson EN, van der Kraan PM and van den Berg WB: Canonical Wnt signaling skews TGF-beta signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal. 26:951–958. 2014. View Article : Google Scholar : PubMed/NCBI
34	Xiao Z, Chen C, Meng T, Zhang W and Zhou Q: Resveratrol attenuates renal injury and fibrosis by inhibiting transforming growth factor-β pathway on matrix metalloproteinase 7. Exp Biol Med (Maywood). 241:140–146. 2016. View Article : Google Scholar : PubMed/NCBI